Bayer AG stock (DE000BAY0017): Crop science and pharma drive earnings recovery in 2025

Bayer AG reported stronger 2025 earnings, led by growth in crop science and pharmaceuticals, as the company continues to manage legacy liabilities and US litigation.

Bayer AG stock has been in focus after the German life sciences group reported improved 2025 full?year results, showing a recovery in underlying earnings driven by its Crop Science and Pharmaceuticals divisions, according to Bayer investor relations as of 02/27/2026.

Core earnings before interest, taxes and special items rose to 10.1 billion euros, up from 8.7 billion euros in 2024, while group sales increased to 49.6 billion euros, reflecting mid?single?digit growth at constant currencies. The improvement comes as Bayer works through legacy liabilities and ongoing US litigation around glyphosate and other products, which have weighed on the group in recent years.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bayer AG
• Sector/industry: Life sciences (pharmaceuticals, crop science, consumer health)
• Headquarters/country: Leverkusen, Germany
• Core markets: Global, with major exposure to the United States and Europe
• Key revenue drivers: Pharmaceuticals and Crop Science divisions
• Home exchange/listing venue: Frankfurt Stock Exchange (ticker: BAYN)
• Trading currency: Euro

Bayer AG: core business model

Bayer AG operates as a global life sciences company focused on healthcare and agriculture, with three main business segments: Pharmaceuticals, Crop Science and Consumer Health. The group develops and markets prescription medicines, over?the?counter products, seeds and crop?protection solutions, as well as digital farming tools.

Pharmaceuticals centers on specialty care, including cardiology, oncology and ophthalmology, while Crop Science supplies seeds, herbicides, insecticides and digital platforms to farmers worldwide. Consumer Health offers well?known brands in pain relief, allergy, digestive health and other self?care categories. This diversified model allows Bayer to tap both healthcare and food?production value chains, though it also exposes the company to regulatory, litigation and commodity?price risks.

Main revenue and product drivers for Bayer AG

In 2025, Pharmaceuticals contributed about 19.1 billion euros in sales, up 5.3% at constant currencies, driven by growth in cardiology and oncology products as well as new launches in ophthalmology, according to Bayer investor relations as of 02/27/2026. The division benefits from an aging population and rising demand for innovative therapies, particularly in the United States and other developed markets.

Crop Science also posted higher sales and operating profit, supported by strong demand for seeds and crop?protection products amid ongoing global food?security concerns. The segment’s performance reflects Bayer’s integration of Monsanto’s portfolio and continued investment in biotechnology and digital farming solutions. Together, Pharmaceuticals and Crop Science form the core of Bayer’s earnings recovery, even as the group continues to address legacy liabilities and US litigation.

Conclusion

Bayer AG’s 2025 results indicate a gradual recovery in earnings, supported by growth in Pharmaceuticals and Crop Science, even as the company continues to address legacy liabilities and US litigation, according to Bayer investor relations as of 02/27/2026. The group’s diversified life?sciences model offers exposure to long?term healthcare and food?security trends, which may be attractive to US investors seeking global diversification.

At the same time, investors must weigh the benefits of this diversification against ongoing legal and regulatory risks, as well as the capital?intensive nature of drug and seed development. Bayer’s ability to maintain innovation, manage litigation outcomes and deliver on its 2026 guidance will likely remain key drivers of the stock’s performance in the coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.